Abstract
Pharmacogenetics explains the implication of DNA variation in the occurrence of adverse drug reactions. The identification of people with genetic susceptibility to develop undesirable events is of great impact for the patient's quality of life and for the country's economy. In this work we performed an extended genomic analysis by next generation sequencing that allowed us to establish a genomic risk profile in a patient who developed rhabdomyolysis secondary to rosuvastatin.
| Translated title of the contribution | Pharmacogenomic dissection of a case of rosuvastatin-induced rhabdomyolysis |
|---|---|
| Original language | Spanish (Colombia) |
| Pages | 1-1 |
| Number of pages | 1 |
| State | Submitted - Nov 1 2019 |
| Event | IV Encuentro de Investigación CIMED - Bogota, Colombia Duration: Nov 1 2019 → … |
Other
| Other | IV Encuentro de Investigación CIMED |
|---|---|
| Country/Territory | Colombia |
| City | Bogota |
| Period | 11/1/19 → … |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Genetics
Fingerprint
Dive into the research topics of 'Pharmacogenomic dissection of a case of rosuvastatin-induced rhabdomyolysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver